Here's Why Grail Stock Surged 55% This Week
Grail Inc GRAL
$126.89
▲ +1.34%
(+$1.68)
🎯 52W High
🔥 High Short Interest
🎢 High Beta
Open
$123.50
Prev Close
$125.21
Day Range
$118.45 – $127.67
52W Range
$41.50 – $126.81
Market Cap
$5.67B
Beta
1.62
EPS (TTM)
$-9.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-06-12 |
| Shares Out. | 42,920,000 |
| Website | grail.com/ ↗ |
| Phone | 13026587581 |
| Employees | 910 |
| Revenue | $44.7M |
| Gross Profit | -$12.6M |
| Net Income | -$110.2M |
| Free Cash Flow | -$296.2M |
| Total Assets | $2.84B |
| Total Liabilities | $301.0M |
| Equity | $2.54B |
About Grail Inc
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Grail Inc is a publicly traded company under the ticker symbol GRAL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)
📰 Latest News for GRAL
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued?
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
Dow Jones Futures Fall As Treasury Yields, Oil Prices Keep Rising. Meta, Everpure, Grail Are Early Movers.
The Holy Grail In Cancer? FDA Panel Backs Blood Tests